Introduction: Morbidity and mortality associated with invasive fungal infections (IFIs) remains
unacceptably high. Such diseases represent a substantial burden to the healthcare system …

Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to healthcare …

The incidence of invasive fungal infections (IFIs) caused by both common and uncommon
opportunistic fungi is increasing along with emerging fungal resistance. Since traditional …

Abstract Purpose of Review Advances in health care over time have led to an evolution in
the epidemiology of invasive fungal infections. There is an increasing concern for antifungal …

The frequency of invasive fungal infections (IFIs) has increased over the last decade with the
rise in at-risk populations of patients. The morbidity and mortality of IFIs are high and …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …

Introduction The incidence of life-threatening invasive fungal infections (IFIs) has increased
significantly in recent years. Current therapeutic options for IFIs are limited. Only four major …

Fungal infections represent an increasing threat to a growing number of immune-and
medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a …

Invasive fungal infections are associated with significant morbidity and mortality, and their
management is restricted to a variety of agents from five established classes of antifungal …

Early treatment of invasive fungal infections (IFIs) is essential for optimal clinical outcomes.
Standard antifungal drugs (polyenes, azoles and echinocandins) are not predictably …